Notice Pursuant to the National Cooperative Research and Production Act of 1993-Rapid Response Partnership Vehicle, 104208-104209 [2024-30403]
Download as PDF
ddrumheller on DSK120RN23PROD with NOTICES1
104208
Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices
positive COVID–19 test result may be
submitted by 3pm the business day
prior to the hearing. Further information
about participation in the hearing will
be posted on the Commission’s website
at https://www.usitc.gov/calendarpad/
calendar.html.
A nonparty who has testimony that
may aid the Commission’s deliberations
may request permission to present a
short statement at the hearing. All
parties and nonparties desiring to
appear at the hearing and make oral
presentations should attend a
prehearing conference, if deemed
necessary, to be held at 9:30 a.m. on
Tuesday, April 15, 2025. Parties shall
file and serve written testimony and
presentation slides in connection with
their presentation at the hearing by no
later than noon on April 14, 2025. Oral
testimony and written materials to be
submitted at the public hearing are
governed by sections 201.6(b)(2),
201.13(f), and 207.24 of the
Commission’s rules. Parties must submit
any request to present a portion of their
hearing testimony in camera no later
than 7 business days prior to the date of
the hearing.
Written submissions—Each party who
is an interested party shall submit a
prehearing brief to the Commission.
Prehearing briefs must conform with the
provisions of § 207.23 of the
Commission’s rules; the deadline for
filing is April 10, 2025. Parties shall also
file written testimony in connection
with their presentation at the hearing,
and posthearing briefs, which must
conform with the provisions of § 207.25
of the Commission’s rules. The deadline
for filing posthearing briefs is April 24,
2025. In addition, any person who has
not entered an appearance as a party to
the investigations may submit a written
statement of information pertinent to
the subject of the investigations,
including statements of support or
opposition to the petition, on or before
April 24, 2025. On May 12, 2025, the
Commission will make available to
parties all information on which they
have not had an opportunity to
comment. Parties may submit final
comments on this information on or
before May 14, 2025, but such final
comments must not contain new factual
information and must otherwise comply
with § 207.30 of the Commission’s rules.
All written submissions must conform
with the provisions of § 201.8 of the
Commission’s rules; any submissions
that contain BPI must also conform with
the requirements of §§ 201.6, 207.3, and
207.7 of the Commission’s rules. The
Commission’s Handbook on Filing
Procedures, available on the
Commission’s website at https://
VerDate Sep<11>2014
20:12 Dec 19, 2024
Jkt 265001
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf, elaborates
upon the Commission’s procedures with
respect to filings.
Additional written submissions to the
Commission, including requests
pursuant to § 201.12 of the
Commission’s rules, shall not be
accepted unless good cause is shown for
accepting such submissions, or unless
the submission is pursuant to a specific
request by a Commissioner or
Commission staff.
In accordance with §§ 201.16(c) and
207.3 of the Commission’s rules, each
document filed by a party to the
investigations must be served on all
other parties to the investigations (as
identified by either the public or BPI
service list), and a certificate of service
must be timely filed. The Secretary will
not accept a document for filing without
a certificate of service.
Authority: These investigations are
being conducted under authority of title
VII of the Tariff Act of 1930; this notice
is published pursuant to § 207.21 of the
Commission’s rules.
By order of the Commission.
Issued: December 16, 2024.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2024–30379 Filed 12–19–24; 8:45 am]
BILLING CODE 7020–02–P
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
DEPARTMENT OF JUSTICE
Antitrust Division
[FR Doc. 2024–30406 Filed 12–19–24; 8:45 am]
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—1EdTech Consortium, Inc.
Notice is hereby given that, on July
16, 2024, pursuant to section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), 1EdTech
Consortium, Inc. (‘‘1EdTech
Consortium’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, Alabama Institute for
Deaf and Blind, East Talladega, AL;
Education Assessment System,
Arlington, VA; University of Georgia,
Athens, GA; School Harbor, Phoenix,
AZ; Ivy Tech Community College,
Indianapolis, IN; MyEducator LLC,
Orem, UT; Mountain Brook Schools,
Mountain Brook, AL; Uinta County
PO 00000
Frm 00137
Fmt 4703
School District #1, Evanston, WY; St.
Charles CUSD 303, St. Charles, IL;
Swedish National Agency for Education
(Statens skolverk), Stockholm,
SWEDEN; Massachusetts Institute of
Technology, Cambridge, MA; and
Vestavia Hills City Schools, Vestavia
Hills, AL, have been added as parties to
this venture.
Also, Washington State Community
and Technical Colleges System,
Olympia, WA; Pearl, Richmond, VA;
New Hanover County Schools,
Wilmington, NC; and Edge Factor Inc.,
Ontario, CANADA, have withdrawn as
parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and 1EdTech
Consortium intends to file additional
written notifications disclosing all
changes in membership.
On April 7, 2000, 1EdTech
Consortium filed its original notification
pursuant to section 6(a) of the Act. The
Department of Justice published a notice
in the Federal Register pursuant to
section 6(b) of the Act on September 13,
2000 (65 FR 55283).
The last notification was filed with
the Department on April 29, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on June 21, 2024 (89 FR 52089).
Sfmt 4703
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Rapid Response
Partnership Vehicle
Notice is hereby given that, on
October 3, 2024, pursuant to section 6(a)
of the National Cooperative Research
and Production Act of 1993, 15 U.S.C.
4301 et seq. (‘‘the Act’’), Rapid Response
Partnership Vehicle (‘‘RRPV’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances.
Specifically, Biointelect Pty, Ltd.,
Sydney, AUSTRALIA; SPI Pharma, Inc.,
E:\FR\FM\20DEN1.SGM
20DEN1
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices
Wilmington, DE; Serimmune, Goleta,
CA; UNITED KINGDOM HEALTH
SECURITY AGENCY (UKHSA),
Salisbury, UNITED KINGDOM;
University of Connecticut, Farmington,
CT; VGXI, Inc., Conroe, TX; ABSS
Solutions, Inc., Upper Marlboro, MD;
BiosYnth SRL, Milan, ITALY; Idevax,
Wijnegem, BELGIUM; IntegerBio, Inc.,
Gaithersburg, MD; Phoreus
Biotechnology, Inc., Olathe, KS;
PrecNA, LLC, North Potomac, MD;
Sepragen Corp., Union City, CA; Trellis
Bioscience, Inc., Redwood City, CA; AB
Validation, Inc., Quebec, CANADA;
AuraVax Therapeutics, Inc., Houston,
TX; CuriRx, Inc., Wilmington, MA; IMA
Evaluations, LLC, dba IMA Clinical
Research, Tarrytown, NY; MustardSeed
PMO, West Chester, PA; Symbiosis.io,
LLC, Smyrna, GA; Tornado
Therapeutics, Boston, MA; Amneal
Pharmaceuticals of New York, LLC,
Brookhaven, NY; Blue Spark
Technologies, Inc., Westlake, OH;
Inhalon Biopharma, Inc., Morrisville,
NC; Intelligene, Inc., Taipei, TAIWAN;
Rocket Science Health US Corp., Seattle,
WA; Rutgers, The State University of
New Jersey, Piscataway, NJ; The
Administrators of the Tulane
Educational Fund, New Orleans, LA;
Verisim Life, Inc., San Francisco, CA;
Arcturus Therapeutics Holdings, Inc.,
San Diego, CA; Blu Zone Bioscience &
Supply Chain Solutions, LLC, Frederick,
MD; Elligo Health Research, Inc.,
Austin, TX; Guide Biomedical
Solutions, LLC, Media, PA; Integral
Molecular, Philadelphia, PA; Komo
Biosciences, Inc., Newton, MA; P95, BV,
Leuven, BELGIUM; Southwest Research
Institute, San Antonio, TX; Statistics &
Data Corp., Tempe, AZ; Stoic Bio, Inc.,
San Diego, CA; Valaria Technical
Consultants, LLC, Westminster, MD;
Vaxine Pty, Ltd., Marion, AUSTRALIA;
Zeteo Biomedical, LLC, Austin, TX;
Concept to Market, LLC, Monrovia, MD;
DSBio Consulting, LLC, Annapolis, MD;
Deimos Biosciences, San Francisco, CA;
GMED North America, Inc., Rockville,
MD; InvisiShield Technologies, Ltd.,
Emeryville, CA; MigVax, Ltd., Kiryat
Shmona, ISRAEL; Polaris Alpha
Advanced Systems, Inc.,
Fredericksburg, VA; Pop Test Oncology,
LLC, Cliffside Park, NJ; Sapphiros,
Boston, MA; Articulate Labs, Inc.,
Dallas, TX; Empatica, Inc., Cambridge,
MA; LifeMine Therapeutics, Inc.,
Cambridge, MA; Luminous
Therapeutics Corp., Columbia, MD;
Nabla Bio, Inc., Cambridge, MA;
Qoolabs, Inc., Carlsbad, CA; Rapid
Novor, Inc., Kitchener, CANADA;
Scorpius BioManufacturing, San
Antonio, TX; Sunflower Therapeutics
VerDate Sep<11>2014
20:12 Dec 19, 2024
Jkt 265001
PBC, Medford, MA; GreenRoads
Diagnostics, Inc., San Diego, CA; Logical
Images, dba ‘‘VisualDx’’, Rochester, NY;
Mirai Biosciences, Cambridge, MA; The
Scripps Research Institute, La Jolla, CA;
AmplifyBio, LLC, West Jefferson, OH;
Andelyn Biosciences, Inc., Columbus,
OH; Binary Pharmaceuticals, LLC, Hot
Springs, AR; BioCina PTY, Ltd., West
Torrens, AUSTRALIA; Cypress
Biologics, LLC, Portland, OR; Fermeate,
Inc., San Francisco, CA; HMH Hospitals
Corp, dba CDI, Nutley, NJ; Meso Scale
Diagnostics, LLC, Rockville, MD;
Systems & Technology Research, LLC,
Woburn, MA; Telesis Bio, San Diego,
CA; Thermo Fisher, South San
Francisco, CA; University of
Massachusetts Lowell, Lowell, MA;
ViQi, Inc., Santa Barbara, CA;
DemeTech Corp., Miami, FL; INFEX
Therapeutics, Alderley Edge, UNITED
KINGDOM; Mercury Bio, Inc., Santa Fe,
NM; Phageolytix, Inc., Jacksonville, FL;
Phenom Pharmaceuticals, LLC, Miami
Beach, FL; RIBOPRO BV, Oss,
NETHERLANDS; RNhale GmbH,
Munich, GERMANY; The University of
Chicago Medicine, Chicago, IL; Bioblue
CMC/Manufacturing Consulting, LLC,
San Diego, CA; Oligo Foundry, Inc., San
Diego, CA; PNUVAX, Inc., Wilmington,
DE; Prosoft Software, Inc., dba Prosoft
Clinical, Chesterbrook, PA; Simon
Williams Pharma Consulting (SWPC),
LLC, Gibbsboro, NJ; Dillico, Meylan,
FRANCE; INFINIFLUIDICS,
Philadelphia, PA; Primrose Bio, Inc.,
San Diego, CA; SIMETRI, Inc., Winter
Park, FL; The Trustees of the University
of Pennsylvania, Philadelphia, PA; and
WCG, Princeton, NJ, have been added as
parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and RRPV intends
to file additional written notifications
disclosing all changes in membership.
On January 5, 2024, RRPV filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Act on April 16, 2024 (89 FR 26928).
The last notification was filed with
the Department on July 11, 2024. The
Department of Justice published a notice
in the Federal Register pursuant to
section 6(b) of the Act on October 11,
2024 (89 FR 82631).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2024–30403 Filed 12–19–24; 8:45 am]
BILLING CODE P
PO 00000
Frm 00138
Fmt 4703
Sfmt 4703
104209
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—UHD Alliance
Notice is hereby given that, on
October 8, 2024, pursuant to section 6(a)
of the National Cooperative Research
and Production Act of 1993, 15 U.S.C.
4301 et seq. (‘‘the Act’’), UHD Alliance,
Inc. (‘‘UHD Alliance’’) filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, TTE Corporation,
Shenzhen, PEOPLE’S REPUBLIC OF
CHINA has been added as a party to this
venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and UHD Alliance
intends to file additional written
notifications disclosing all changes in
membership.
On June 17, 2015, UHD Alliance filed
its original notification pursuant to
section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to section
6(b) of the Act on July 17, 2015 (80 FR
42537).
The last notification was filed with
the Department on July 8, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on September 26, 2024 (89 FR
78904).
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
[FR Doc. 2024–30412 Filed 12–19–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Subcutaneous Drug
Development & Delivery Consortium,
Inc.
Notice is hereby given that, on
October 4, 2024, pursuant to section 6(a)
of the National Cooperative Research
and Production Act of 1993, 15 U.S.C.
4301 et seq. (‘‘the Act’’), Subcutaneous
Drug Development & Delivery
E:\FR\FM\20DEN1.SGM
20DEN1
Agencies
[Federal Register Volume 89, Number 245 (Friday, December 20, 2024)]
[Notices]
[Pages 104208-104209]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-30403]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Rapid Response Partnership Vehicle
Notice is hereby given that, on October 3, 2024, pursuant to
section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership
Vehicle (``RRPV'') has filed written notifications simultaneously with
the Attorney General and the Federal Trade Commission disclosing
changes in its membership. The notifications were filed for the purpose
of extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Biointelect Pty, Ltd., Sydney, AUSTRALIA; SPI Pharma,
Inc.,
[[Page 104209]]
Wilmington, DE; Serimmune, Goleta, CA; UNITED KINGDOM HEALTH SECURITY
AGENCY (UKHSA), Salisbury, UNITED KINGDOM; University of Connecticut,
Farmington, CT; VGXI, Inc., Conroe, TX; ABSS Solutions, Inc., Upper
Marlboro, MD; BiosYnth SRL, Milan, ITALY; Idevax, Wijnegem, BELGIUM;
IntegerBio, Inc., Gaithersburg, MD; Phoreus Biotechnology, Inc.,
Olathe, KS; PrecNA, LLC, North Potomac, MD; Sepragen Corp., Union City,
CA; Trellis Bioscience, Inc., Redwood City, CA; AB Validation, Inc.,
Quebec, CANADA; AuraVax Therapeutics, Inc., Houston, TX; CuriRx, Inc.,
Wilmington, MA; IMA Evaluations, LLC, dba IMA Clinical Research,
Tarrytown, NY; MustardSeed PMO, West Chester, PA; Symbiosis.io, LLC,
Smyrna, GA; Tornado Therapeutics, Boston, MA; Amneal Pharmaceuticals of
New York, LLC, Brookhaven, NY; Blue Spark Technologies, Inc., Westlake,
OH; Inhalon Biopharma, Inc., Morrisville, NC; Intelligene, Inc.,
Taipei, TAIWAN; Rocket Science Health US Corp., Seattle, WA; Rutgers,
The State University of New Jersey, Piscataway, NJ; The Administrators
of the Tulane Educational Fund, New Orleans, LA; Verisim Life, Inc.,
San Francisco, CA; Arcturus Therapeutics Holdings, Inc., San Diego, CA;
Blu Zone Bioscience & Supply Chain Solutions, LLC, Frederick, MD;
Elligo Health Research, Inc., Austin, TX; Guide Biomedical Solutions,
LLC, Media, PA; Integral Molecular, Philadelphia, PA; Komo Biosciences,
Inc., Newton, MA; P95, BV, Leuven, BELGIUM; Southwest Research
Institute, San Antonio, TX; Statistics & Data Corp., Tempe, AZ; Stoic
Bio, Inc., San Diego, CA; Valaria Technical Consultants, LLC,
Westminster, MD; Vaxine Pty, Ltd., Marion, AUSTRALIA; Zeteo Biomedical,
LLC, Austin, TX; Concept to Market, LLC, Monrovia, MD; DSBio
Consulting, LLC, Annapolis, MD; Deimos Biosciences, San Francisco, CA;
GMED North America, Inc., Rockville, MD; InvisiShield Technologies,
Ltd., Emeryville, CA; MigVax, Ltd., Kiryat Shmona, ISRAEL; Polaris
Alpha Advanced Systems, Inc., Fredericksburg, VA; Pop Test Oncology,
LLC, Cliffside Park, NJ; Sapphiros, Boston, MA; Articulate Labs, Inc.,
Dallas, TX; Empatica, Inc., Cambridge, MA; LifeMine Therapeutics, Inc.,
Cambridge, MA; Luminous Therapeutics Corp., Columbia, MD; Nabla Bio,
Inc., Cambridge, MA; Qoolabs, Inc., Carlsbad, CA; Rapid Novor, Inc.,
Kitchener, CANADA; Scorpius BioManufacturing, San Antonio, TX;
Sunflower Therapeutics PBC, Medford, MA; GreenRoads Diagnostics, Inc.,
San Diego, CA; Logical Images, dba ``VisualDx'', Rochester, NY; Mirai
Biosciences, Cambridge, MA; The Scripps Research Institute, La Jolla,
CA; AmplifyBio, LLC, West Jefferson, OH; Andelyn Biosciences, Inc.,
Columbus, OH; Binary Pharmaceuticals, LLC, Hot Springs, AR; BioCina
PTY, Ltd., West Torrens, AUSTRALIA; Cypress Biologics, LLC, Portland,
OR; Fermeate, Inc., San Francisco, CA; HMH Hospitals Corp, dba CDI,
Nutley, NJ; Meso Scale Diagnostics, LLC, Rockville, MD; Systems &
Technology Research, LLC, Woburn, MA; Telesis Bio, San Diego, CA;
Thermo Fisher, South San Francisco, CA; University of Massachusetts
Lowell, Lowell, MA; ViQi, Inc., Santa Barbara, CA; DemeTech Corp.,
Miami, FL; INFEX Therapeutics, Alderley Edge, UNITED KINGDOM; Mercury
Bio, Inc., Santa Fe, NM; Phageolytix, Inc., Jacksonville, FL; Phenom
Pharmaceuticals, LLC, Miami Beach, FL; RIBOPRO BV, Oss, NETHERLANDS;
RNhale GmbH, Munich, GERMANY; The University of Chicago Medicine,
Chicago, IL; Bioblue CMC/Manufacturing Consulting, LLC, San Diego, CA;
Oligo Foundry, Inc., San Diego, CA; PNUVAX, Inc., Wilmington, DE;
Prosoft Software, Inc., dba Prosoft Clinical, Chesterbrook, PA; Simon
Williams Pharma Consulting (SWPC), LLC, Gibbsboro, NJ; Dillico, Meylan,
FRANCE; INFINIFLUIDICS, Philadelphia, PA; Primrose Bio, Inc., San
Diego, CA; SIMETRI, Inc., Winter Park, FL; The Trustees of the
University of Pennsylvania, Philadelphia, PA; and WCG, Princeton, NJ,
have been added as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and RRPV intends to file additional
written notifications disclosing all changes in membership.
On January 5, 2024, RRPV filed its original notification pursuant
to section 6(a) of the Act. The Department of Justice published a
notice in the Federal Register pursuant to section 6(b) of the Act on
April 16, 2024 (89 FR 26928).
The last notification was filed with the Department on July 11,
2024. The Department of Justice published a notice in the Federal
Register pursuant to section 6(b) of the Act on October 11, 2024 (89 FR
82631).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-30403 Filed 12-19-24; 8:45 am]
BILLING CODE P